Healthcare services company Sotera Health (NASDAQ: SHC) reported Q3 2026 results topping the market’s revenue expectations, with sales up 4.4% year on year to $324.9 million. The company expects the full year’s revenue to be around $1.24 billion, close to analysts’ estimates. Its non-GAAP profit of $0.29 per share was 8% above analysts’ consensus estimates.

Is now the time to buy SHC? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Sotera Health’s third quarter results showed steady growth, but the market reacted negatively, with shares declining after the release. Management attributed revenue and earnings momentum to robust execution in Sterigenics and Nelson Labs, while acknowledging emerging weakness in the European medical device segment. CEO Alton Shader noted, “Sterigenics continued to perform well, generating 8.2% constant currency revenue growth,” but flagged that “some softness in the med device market” persisted late in the quarter and into Q4. The company also benefited from improved operational productivity and contributions from its North Carolina X-ray facility.

Looking ahead, Sotera Health’s guidance reflects a stable but cautious outlook shaped by ongoing uncertainty in the medical device market. Management expects continued growth from Sterigenics and Nelson Labs, but anticipates more moderate results in the final quarter as customer optimism softens. Shader explained, “We are not expecting the sequential Q4 growth that we normally see in Sterigenics, and this really informed our guide.” The company is maintaining a disciplined approach to capital allocation and expects a step-down in capital expenditures, supporting its goal of stronger free cash flow into next year.

Key insights from management’s remarks

Management identified Sterigenics and Nelson Labs as key drivers of the quarter’s results, while noting medical device market headwinds and project-based growth in expert advisory services.

• Sterigenics growth resilience: Despite emerging softness in the medical device end market, Sterigenics delivered 8.2% constant currency revenue growth, supported by favorable pricing, increased volumes, and contributions from the newly operational North Carolina X-ray facility.
• Nelson Labs project execution: Nelson Labs benefited from a surge in expert advisory services, addressing urgent regulatory testing needs for customers and driving 9.2% constant currency revenue growth. This project-based boost, however, is not expected to persist at the same level into the next quarter.
• Nordion margin gains amid timing shifts: Nordion’s revenue declined due to the timing of Cobalt-60 harvests, yet the segment improved income margins through operational productivity and favorable pricing, outperforming internal expectations for the period.
• Customer optimism moderating: Management observed a broad-based reduction in customer optimism, particularly among European medical device clients, resulting in less sequential revenue growth than usual from Q3 to Q4.
• Capex discipline and balance sheet progress: The company is on track with its capacity expansion projects and EO facility upgrades, while improved cash generation and a net leverage reduction to 2.9x were recognized by a recent Moody’s credit rating upgrade.

Drivers of future performance

Sotera Health’s outlook is shaped by softened demand in medical device markets, stable U.S. trends, and disciplined investment priorities.

• Medical device end market caution: Management expects ongoing softness in Europe’s medical device sector to limit sequential growth for Sterigenics in Q4, though U.S. demand remains stable. Shader emphasized that the guidance assumes a “reduction in optimism” among customers, especially in Europe.
• Project-based growth moderation: While Nelson Labs saw strong Q3 results from expert advisory services, management anticipates more typical growth rates ahead as project-based tailwinds normalize. There is no expectation of a lasting mix shift toward these services.
• Capital allocation focus: With key facility upgrades nearing completion and net leverage within target range, management plans a meaningful reduction in capital expenditures next year. This supports improved free cash flow, but the company will continue to prioritize organic growth and targeted M&A opportunities in sterilization services.

Catalysts in upcoming quarters

In the upcoming quarters, our team will watch (1) the pace of recovery or further deterioration in European medical device demand, (2) utilization and customer ramp-up at the North Carolina X-ray facility, and (3) the sustainability of project-driven momentum in Nelson Labs. Execution on facility upgrades and capital expenditure discipline will also be important measures of management’s effectiveness.

Sotera Health Company currently trades at $16.03, down from $17.74 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.